NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




NCI Community Oncology Research Program - Protocol Summary

Alliance A011502 - "A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL"

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.


This summary is not intended to be used in place of the full eligibility & treatment information in the protocol.
 

Please contact NCORP-KC for complete protocol information.



Print This Summary

Breast Clinical Trial

CANCER TYPE: Stage III
RESEARCH BASE: Alliance
NCT NUMBER: NCT02927249
HIPPA FORM: DOWNLOAD HIPPA FORM

Consent Form: VIEW CONSENT FORM
UPDATED ON 07/27/2018 (15:59:14)

BRIEF DESCRIPTION

Breast carcinoma, node positive, HER-2 negative, stage II or III, aspirin 300mg vs. placebo x 5 years.  DCP-001 Eligible



NOTES


Treatment  (Supplied drug:  aspirin/placebo)

Arm 1:

Aspirin 300mg daily for 5 years

 

Arm 2:

Placebo daily for 5 years



ELIGIBILITY

Eligibility

  • Histologic documentation of women or men with node positive, HER2 negative, anatomic stage II or III breast carcinoma within one year of diagnosis and free of recurrence.
  • Any ER/PgR status allowed.
  • Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined the treating physician, is allowed. The last dose of chemotherapy or radiation therapy must be at least 60 days prior to study registration. Concurrent hormonal therapy will be allowed.
  • Regular NSAID/aspirin use (defined as ≥ 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for one year prior to study entry and throughout the study period. Participants will be encouraged to use acetaminophen for minor pain and fever.
  • Patients must be enrolled within 1 year after diagnosis.
  • Age > 18 and < 70 years of age.
  • ECOG performance status 0-2.
  • Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention.  For patients who are Helicobacter pylori positive, a course of Helicobacter pylori eradication treatment must have been completed.
  • No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention.
  • No history of any prior stroke (hemorrhagic or ischemic).
  • No concurrent anticoagulation with warfarin or heparin or clopidogrel or oral direct thrombin inhibitors.
  • No history of atrial fibrillation or myocardial infarction.
  • No history of grade 4 hypertension, defined as hypertension resulting in life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis).
  • No chronic (duration >30 days) daily use of oral steroids.
  • No known allergy to aspirin.
  • No prior malignancy of any type within the past 5 years other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
  • Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use.
  • Required Initial Laboratory Values:  Platelet count ≥ 100,000/mm3





  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA